Conflict of interest
Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis
Article first published online: 7 JAN 2013
© 2013 The Authors Journal of the European Academy of Dermatology and Venereology © 2013 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 28, Issue 2, pages 192–203, February 2014
How to Cite
Mamolo, C., Harness, J., Tan, H. and Menter, A. (2014), Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 28: 192–203. doi: 10.1111/jdv.12081
CM and HT are employees of Pfizer Inc.; JH was a full-time employee of Pfizer Inc. during the conduct and reporting of the study and now works at Novartis Pharma AG, Basel, Switzerland. AM has been on the Advisory Board (A), been a consultant to (C), been an investigator for (I), been a speaker for (S), obtained a research grant from (G) or obtained honoraria from (H) the following 16 groups: Abbott (A, C, I, S, G, H), Allergan (I, G), Amgen (A, C, I, S, G, H), Astellas (A, C, I, S, G, H), Asubio (I, G), Celgene (I, G), Centocor (A, C, I, S, G, H), DUSA (I, G), Eli Lilly (C, I, G), Galderma (A, C, S, H), Genentech (A, C, I, S, G, H), Novartis (I, G), Novo Nordisk (I, G), Pfizer Inc. (I, G), Promius (I, G), Stiefel (C, I, G, H), Syntrix Biosystems (I, G), Warner Chilcott (A, C, I, S, H) and Wyeth (A, C, I, S, H)
This study was funded by Pfizer Inc.
- Issue published online: 13 JAN 2014
- Article first published online: 7 JAN 2013
- Manuscript Accepted: 26 NOV 2012
- Manuscript Received: 31 JUL 2012
- Pfizer Inc
Options for accessing this content:
- If you have access to this content through a society membership, please first log in to your society website.
- If you would like institutional access to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions and you will be able to log in to access content. Some users may also log in directly via OpenAthens.
Please note that there are currently a number of duplicate entries in the list of institutions. We are actively working on fixing this issue and apologize for any inconvenience caused.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.